Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma


This research study is a Pilot Study. Pilot studies are conducted to see if it is practical to do this type of research on a larger scale in the future. The pilot part of the study is to assess the possibility of using pencil beam proton radiation to treat the studied type of cancer. Proton radiation is used for many other types of malignancies, but its use for the treatment of anal cancer has been limited. The treatment is still being studied as research doctors are trying to find out more about its use in the treatment of anal cancer. Proton beam radiation therapy is an FDA approved radiation delivery system.

Patients are being asked to participate in this study because they have cancer in the anal canal. Conventional radiation therapy with photons in combination with 5-FU and mitomycin-C is used as standard treatment for many patients with anal cancer.

In this research study the investigators are looking at another type of radiation called proton radiation, which is known to spare surrounding tissue and organs from radiation. Proton radiation delivers radiation to the area requiring radiation but delivers no dose beyond the region requiring treatment. There are several techniques that can be used to deliver proton radiation therapy. One of the newer techniques, called pencil beam scanning, allows for more accurate delivery of radiation to the tumor and further reduces the amount of normal tissue exposed to radiation. Most proton patients are treated with a number of beams that study doctors conform to the shape of the tumor. Pencil beam scanning delivers radiation with a single, narrow proton beam that is swept over the area of the tumor. This may reduce side effects that patients would normally experience with conventional radiation therapy or other means of delivering proton radiation therapy, and also minimizes treatment time.

In this research study, the investigators are evaluating the effectiveness of using pencil beam proton radiation delivered to reduce side effects associated with radiation treatment.

Study Start Date

July 2013

Estimated Completion Date

July 2016


  • Drug: 5-fluorouracil
  • Radiation: Pencil Beam scanning Radiation
  • Drug: Mitomycin-C


  • Oncology: Colorectal Cancer/Polyps,Pharmacology/Therapy,Radiation Oncology
  • Radiology: Radiotherapy (XRT)

MeSH Terms

  • Anal Canal
  • Carcinoma
  • Colorectal Neoplasms

Study ID

Massachusetts General Hospital -- 13-075



Trial ID


Study Type


Trial Phase

Phase 0

Enrollment Quota



Massachusetts General Hospital

Inclusion Criteria

  • Histologically or cytologically confirmed invasive primary squamous, basaloid or cloacogenic carcinoma of the anal canal
  • Life expectancy of at least 3 months

Exclusion Criteria

  • Prior abdominopelvic radiotherapy
  • Prior systemic therapy for anal cancer
  • Pregnant or breastfeeding
  • Receiving other investigational agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to mitomycin-C or 5-fluorouracil
  • Prior surgery for cancer of the anus that removed all macroscopic anal cancer
  • Uncontrolled intercurrent illness
  • AIDS based on current CDC definition
  • Other immunocompromised status
  • Individuals with a history of a different malignancy are ineligible except for the following circumstances: disease-free for at least 5 years and at low risk for recurrence or cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin




18 Years and older

Accepts Healthy Volunteers


Study Locations and Contact Information (2)

Study Location Distance Name Phone Email
Massachusetts General Hospital - Boston, Massachusetts 2.8 miles Jennifer Wo MD 617-726-7559
Roberts Proton Therapy Center of the University of Pennsylvania - Philadelphia, Pennsylvania 270.8 miles Edgar BenJosef MD None None provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.